Skip to main content

Table 2 Characteristics of patients in TDF+PI/r and control groups at the end of 48 weeeks a

From: Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study

Variable

TDF+PI/r group (n=75)

Control group (n=75)

P

BMI b (kg/m 2 )

21.9 (20.1-23.7)

21.0 (19.3-22.9)

0.083

CD4 cell count (cells/μl)

279 (196–380.5)

292.0 (207.0-394.0)

0.736

Viral load (log 10 copies/ml)

1.6 (1.6-1.8)

1.6 (1.6-1.7)

0.064

Proteinuria

  

0.071

  Positive

9 (12)

3(4)

 

  Negative

66 (88)

72 (96)

 

Serum creatinine (μmol/L)

79 (70–85)

69.7 (62–80.3)

<0.001

eGFR c (ml/min/1.73 m 2 )

93.0 (82.4-104.0)

101.6 (86.8-121.6)

0.009

Change in eGFR (ml/min/1.73 m 2 )

−8.8(−18.5-3.3)

6.4(−3.8-16.5)

<0.001

  1. Note.
  2. aValues are expressed as median (interquartile range, IQR) or number (percentage).
  3. bBMI =weight (kg)/(height (m))2.
  4. ceGFR = 186 × (Serum creatinine (mg/dL))-1.154 × (age(years))-0.203 × (0.742 if female).